Cargando…

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma

SIMPLE SUMMARY: Lung cancer causes the largest number of cancer-related deaths worldwide. Circulating tumor DNA (ctDNA) has been suggested as a diagnostic and prognostic biomarker in non-small cell lung cancer, but the optimal target for measuring ctDNA has not been established. We aimed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Sara W. C., Andersen, Rikke F., Petersen, Lena Marie S., Hager, Henrik, Hilberg, Ole, Jakobsen, Anders, Hansen, Torben F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763990/ https://www.ncbi.nlm.nih.gov/pubmed/33322500 http://dx.doi.org/10.3390/cancers12123728

Ejemplares similares

Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer
por: Wen, Sara W. C., et al.
Publicado: (2021)

NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Wen, Sara Witting Christensen, et al.
Publicado: (2023)

The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
por: Wen, Sara Witting Christensen, et al.
Publicado: (2021)

Genetic and phenotypic continuum of HOXA genes: A case with double HOXA9/HOXA13 mutations
por: Jaouadi, Hager, et al.
Publicado: (2023)

Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review
por: Wen, Sara Witting Christensen, et al.
Publicado: (2022)

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
por: Borg, Morten, et al.
Publicado: (2023)

Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients
por: Borg, Morten, et al.
Publicado: (2022)

Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer
por: Thomsen, Caroline B., et al.
Publicado: (2020)

HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas
por: Jäger, Daniela, et al.
Publicado: (2017)

Promoter Methylation of Two HOXA9 and NISCH Genes in Opium Users
por: Mahmoodi, Majid, et al.
Publicado: (2023)

Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer
por: Kristensen, Lasse Sommer, et al.
Publicado: (2012)

Expression Landscape and Functional Roles of HOXA4 and HOXA5 in Lung Adenocarcinoma
por: Gao, Li, et al.
Publicado: (2022)

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
por: Jensen, Lars Henrik, et al.
Publicado: (2019)

Comorbidity among Danish lung cancer patients before and after initial cancer diagnosis
por: Gouliaev, Anja, et al.
Publicado: (2020)

DNA Methylation of HOXA11 Gene as Prognostic Molecular Marker in Human Gastric Adenocarcinoma
por: Ignatavicius, Povilas, et al.
Publicado: (2022)

Study of Promoter Methylation Patterns of HOXA2, HOXA5, and HOXA6 and Its Clinicopathological Characteristics in Colorectal Cancer
por: Li, Daojiang, et al.
Publicado: (2019)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Comprehensive Landscape of HOXA2, HOXA9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in Prostate Cancer
por: Song, Yan-ping, et al.
Publicado: (2022)

A long-range interactive DNA methylation marker panel for the promoters of HOXA9 and HOXA10 predicts survival in breast cancer patients
por: Park, Seong-Min, et al.
Publicado: (2017)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer
por: Faaborg, Louise, et al.
Publicado: (2022)

Study protocol: pneumonia and inhaled corticosteroid treatment patterns in chronic obstructive pulmonary disease – a cohort study using sequence analysis (PICCS)
por: Klitgaard, Allan, et al.
Publicado: (2023)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Spindler, K-L G, et al.
Publicado: (2014)

The Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer
por: Hansen, Torben F., et al.
Publicado: (2010)

Direct and indirect economic burden of lung cancer in Denmark a nationwide study
por: Gouliaev, Anja, et al.
Publicado: (2021)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation
por: Reinert, Thomas, et al.
Publicado: (2012)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national population-based study
por: Rittig, Anne Hald, et al.
Publicado: (2019)

National Epidemiological Case–Control Study of Pharmacological Smoking Cessation Treatment in Danish Patients with Chronic Obstructive Pulmonary Disease
por: Andelius, Dea Kejlberg, et al.
Publicado: (2021)

Pharmacological smoking cessation of adults aged 30–50 years with COPD
por: Andelius, Dea Kejlberg, et al.
Publicado: (2022)

PRMT5 Prevents Cardiomyocyte Hypertrophy via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression
por: Cai, Sidong, et al.
Publicado: (2020)

Hoxa11-mediated reduction of cell migration contributes to myeloid sarcoma formation induced by cooperation of MLL/AF10 with activating KRAS mutation in a mouse transplantation model: Hoxa11 in myeloid sarcoma formation
por: Fu, Jen-Fen, et al.
Publicado: (2022)

The prognostic value of homeobox A9 (HOXA9) methylation in solid tumors: a systematic review and meta-analysis
por: Cai, Hai, et al.
Publicado: (2021)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma
por: Elghissassi, Ibrahim, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ir0a0e314qvkisdjag4dfv3udm